AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00630838
Drug: VSL#3
RxNorm normalized name: VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.~E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding.
Trial: NCT00630838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
Trial: NCT04456816
Drug: 100 mg AP1189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg AP1189 tablet
Trial: NCT04456816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet
Trial: NCT01074060
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02045940
Drug: GSK2881078
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
Trial: NCT02045940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
Trial: NCT03487562
Drug: DWP14012 Bmg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 Bmg
Trial: NCT03487562
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg
Trial: NCT03029572
Drug: Diet supplementation
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutriment supplementation therapy
Trial: NCT03457701
Drug: Ferrous sulfate containing the stable iron isotope (57Fe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.
Trial: NCT03457701
Drug: Ferrous sulfate containing the stable iron isotope (58Fe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).
Trial: NCT04017546
Drug: CYC065
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT00794716
Drug: NRL972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.
Trial: NCT02931357
Drug: Calgel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
Trial: NCT03089229
Drug: HAT01H Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Trial: NCT03089229
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Trial: NCT03127072
Drug: chemotherapy ± target therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy ± target therapy
Trial: NCT04600115
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
Trial: NCT00719511
Drug: Purified allergen integrated in a Patch system
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epicutaneous application of a patch
Trial: NCT04192292
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given at very low dose as a physiological stimulus on the beta cell not as medical treatment. 20mg gliclazide is being used in this study.
Trial: NCT01648517
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
Trial: NCT01648517
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
Trial: NCT00911170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a single subcutaneous injection using a pre-filled syringe.
Trial: NCT00911170
Drug: Standard Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant received one of the following chemotherapy regimens at the discretion of treating physician:~FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil.
Trial: NCT06593743
Drug: Intraanal NRL001 Gel 2 strengths
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single application of 3.0% or 1.0% Gel
Trial: NCT06593743
Drug: NRL001: 10mg suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRL001 10mg suppository applied to rectum.
Trial: NCT02581657
Drug: PE0139 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE0139 Injection
Trial: NCT02530034
Drug: Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00663208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
Trial: NCT00318032
Drug: multi-factorial intervention
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02496715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaler
Trial: NCT02876211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 capsules/three times per week
Trial: NCT03840421
Drug: cisplatin and fluorouracil
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive fluorouracil (800mg/m2 d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
Trial: NCT01069692
Drug: SBR759A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBR759A 6g daily
Trial: NCT01069692
Drug: SBR759A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator 0g daily
Trial: NCT01069692
Drug: SBR759A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBR759A 3g daily
Trial: NCT01069692
Drug: SBR759A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9g daily
Trial: NCT01069692
Drug: SBR759A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12g daily
Trial: NCT01266967
Drug: GSK2118436
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
Trial: NCT02493712
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 capsules of IBD98-M, twice a day
Trial: NCT02493712
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules of IBD98-M
Trial: NCT02493712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00777504
Drug: stop oral angiogenesis inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see under 'study arms'
Trial: NCT04437654
Drug: Anticoagulation group(Apixaban group)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
Trial: NCT03764241
Drug: Vitamin K Antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: warfarin (INR 2.0-2.5) will be applied for 3 months unless severe safety outcome occur. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
Trial: NCT02405078
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given standard salvage chemotherapy
Trial: NCT01184092
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
Trial: NCT01184092
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
Trial: NCT06176079
Drug: Hyperpolarized (HP) 13C
RxNorm normalized name: (13C)urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.
Trial: NCT06176079
Drug: Hyperpolarized 13C-Urea
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given intravenously (IV)
Trial: NCT02318706
Drug: DS-5565
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02318706
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01347112
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill twice daily for 12 weeks
Trial: NCT03706755
Drug: Norepinephrine: 1mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intervention:Parturients will receive Norepinephrine: a bolus of 1 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.5 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
Trial: NCT03706755
Drug: Norepinephrine 0,5mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intervention: Parturients will receive Norepinephrine: a bolus of 0.5 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.25 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
Trial: NCT01345162
Drug: Ketorolac postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 10mg 1cp x 3/die
Trial: NCT01345162
Drug: postoperative Patrol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die
Trial: NCT01345162
Drug: intraoperative analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac 30 mg iv
Trial: NCT01345162
Drug: intraoperative analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg if Weight over 50 kg, 50 mg if weight below 50 kg
Trial: NCT01601236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.
Trial: NCT04950647
Drug: Nitroketazine Group 2
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).
Trial: NCT04950647
Drug: placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).
Trial: NCT03373422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT02798627
Drug: NS2359
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.
Trial: NCT02798627
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills identical in appearance to the NS2359 will be provided
Trial: NCT03098875
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General anesthesia using remifentanil as an analgesic.
Trial: NCT03217604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with placebo
Trial: NCT02671708
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Trial: NCT01969136
Drug: Drug: EVP-6124
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01969136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03137381
Drug: CTP-543 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as tablets.
Trial: NCT04589741
Drug: CAV/IE alternate chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV/IE alternate chemotherapy (regimen1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and regimen2: IFO 1.5g/m2 D1-5 + VP-16 90mg/m2 D1-5, IV drip), regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.~Patiens with disease control (CR+PR+SD) and tolerable adverse reactions were treated continuously with a maximum of 8-10 cycles. If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (≥ 60 years old: 35mg/m2, \< 60 year old: 40mg/m2) or IE regimen can be used. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment.
Trial: NCT03779295
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The entire face (both halves) will receive clindamycin.
Trial: NCT02190994
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: used intravenously
Trial: NCT01813162
Drug: Vaginal product
RxNorm normalized name: Vaginal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02199184
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02199184
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00425802
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01161277
Drug: Placebo sugar pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 1-2 pills depending on subject weight
Trial: NCT03430284
Drug: Pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy is individualized. 1.Glucose-lowering agents:~1. Oral antihyperglycemic agents:Biguanides;Sulfonylureas;Thiazolidinediones;Glinides;a-Glucosidase inhibitors;DPP-4 inhibitors;Sodium-glucose cotransporter 2 inhibitors~2. GLP-1 receptor agonist~3. Insulin:Rapid-acting analogs;Short-acting analogs;Intermediate-acting analogs;Basal insulin analogs;Premixed insulin products~2.Blood pressure-lowering agents~(1)ACE inhibitor;(2)Angiotensin receptor blockers (ARBs);(3)Calcium channel blockers (CCB);(4)Diuretics;(5)β-blockers;(6)α1-blockers~3.Lipid-modifying agents~(1)Statins;(2)Fibrates;(3)Others: Nicotinic Acid, Ezetimibe,Probucol,Bile Acid Sequestrants,Policosanol,etc.~4.Medications for weight management~(1)Glucose-lowering agents associated with weight loss;(2)Orlistat;(3)Metabolic Surgery~The above medications are individualized to maintain the risk factors (blood glucose, serum lipid profiles, blood pressure and weight) at appropriate levels.
Trial: NCT00497081
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 30 mg daily for 3 months
Trial: NCT03631251
Drug: Open Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
Trial: NCT02098785
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT02956226
Drug: Cannabinoids - 99% pure cannabinoids mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
Trial: NCT02481674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
Trial: NCT02956226
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil and flavors solution.
Trial: NCT02956226
Drug: Cannabinoids - whole plant extract
RxNorm normalized name: century plant whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
Trial: NCT01006785
Drug: DLBS1425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 150 mg daily for 12 - 16 weeks of treatment
Trial: NCT01006785
Drug: DLBS1425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 300 mg daily for 12 - 16 weeks of treatment
Trial: NCT03469557
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will be treated with capecitabine 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
Trial: NCT00002715
Drug: Stanford V regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002715
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A component of the Stanford V regimen.
Trial: NCT03911401
Drug: 0.3% OPA-15406
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT03911401
Drug: 1% OPA-15406
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT03911401
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT04638543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02345447
Drug: Herbal-based medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aconitum napellus, Capsicum annuum; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum; Hydrastis canadensis; Iodum; Natrium tetraboracicum; Sambucus nigra; Sanguinaria canadensis
Trial: NCT02345447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous ethanol solution non-distinguishable from verum
Trial: NCT00368069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets, 2 tablets once daily
Trial: NCT00399542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00635193
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
Trial: NCT02225626
Drug: Other: standard breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration